Biogen Inc. (Cambridge, MA) is a biotechnology company with deep expertise in multiple sclerosis (MS), neurodegenerative diseases, and novel biological therapies. Biogen's connection to the ceramide/sphingolipid pathway comes primarily through its development of [sphingosine-1-phosphate (S1P) receptor modulators](/mechanisms/sphingolipid-signaling-neurodegeneration) for MS, and through exploratory programs evaluating S1P modulation in Alzheimer's disease and other neurodegenerative conditions.
Biogen was the first to bring an S1P receptor modulator to market (fingolimod, licensed from Novartis under the name Gilenya for MS), and continues to explore the potential of S1P pathway modulation for neuroprotection across the neurodegeneration spectrum.
S1P Receptor Biology
The Sphingolipid Rheostat
The balance between [ceramide](/mechanisms/ceramide-signaling-neurodegeneration) and [sphingosine-1-phosphate (S1P)](/mechanisms/sphingolipid-signaling-neurodegeneration) determines cell fate:
High ceramide / low S1P → apoptosis, cell death
Low ceramide / high S1P → cell survival, proliferation, neuroprotection
S1P receptors (S1PR1-5) are GPCRs that mediate the pro-survival effects of S1P. S1P receptor modulators shift the rheostat toward neuroprotection by:
Biogen has developed derivatives of fingolimod with improved properties:
BG-10 Mechanism: Second-generation S1P receptor modulator with enhanced CNS penetration and improved selectivity.
Development Status:
Preclinical development for MS and AD
Improved S1PR5 selectivity may enhance oligodendrocyte protection
Potential for reduced cardiac side effects vs fingolimod
Preclinical Profile:
Enhanced remyelination in cuprizone mouse model
Reduced neuroinflammation in EAE
Promising AD mouse model data (reduced amyloid pathology)
2. S1P Receptor Biology Collaboration
Biogen collaborates with academic centers on:
| Program | Collaborator | Focus | |---------|-------------|-------| | S1PR5 in ALS | Columbia University | Oligodendrocyte protection in ALS | | S1P in AD | Stanford University | Amyloid clearance mechanisms | | S1P in PD | UCSF | Neuroinflammation modulation |
3. Anti-LINGO-1 (BIIB092)
Biogen's anti-LINGO-1 antibody promotes remyelination. LINGO-1 is a negative regulator of oligodendrocyte differentiation. While not a sphingolipid agent, it represents Biogen's CNS repair strategy: